McKay AJ, et al. - Given the current and probable future prevalence of undiagnosed familial hypercholesterolaemia (FH) in the UK, researchers tested the cost-effectiveness of universal screening (US) as an adjunct to cascade testing (CT). An incremental analysis with a healthcare perspective was carried out to compare seven cholesterol and/or mutation-based US ± reverse cascade testing (RCT) alternatives with no US. Using a decision model, costs and outcomes were estimated for cohorts exposed to the US component of each strategy. They found that by a strategy involving universal cholesterol screening followed by diagnostic genetic testing and RCT for FH was the most cost-effective under a UK conventional willingness-to-pay threshold.